Louise Chen

Edward Tenthoff

Sami Corwin

John Hester

- Mesoblast reported **revenue from cell therapy products of US$17.2 million** for the full year ended June 30, 2025, representing a **191% increase** over the prior year, primarily driven by the successful commercial launch of **Ryoncil®**.  **[1345099_0001345099-25-000068_exhibit991.htm:0]** **[1345099_0001345099-25-000068_exhibit992.htm:7]** **[1345099_0001345099-25-000068_exhibit991.htm:4]** 
- The company recorded a **net loss after tax of US$102.1 million** for FY2025, with a **net loss attributable to ordinary shareholders of 8.46 US cents per share**.  **[1345099_0001345099-25-000068_exhibit991.htm:4]** **[1345099_0001345099-25-000068_exhibit991.htm:8]** 
- **Ryoncil®**, the first and only FDA-approved mesenchymal stromal cell product, became commercially available on **March 28, 2025**, for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients.  **[1345099_0001345099-25-000068_exhibit991.htm:0]** **[1345099_0001345099-25-000068_exhibit991.htm:1]** **[1345099_0001345099-25-000068_exhibit992.htm:4]** 
- As of June 30, 2025, Mesoblast had **US$162 million in cash on hand**.  **[1345099_0001345099-25-000068_exhibit991.htm:0]** **[1345099_0001345099-25-000068_exhibit992.htm:7]** 
- The company is pursuing label expansion for Ryoncil® in adults with severe SR-aGvHD and inflammatory colitis, and plans Biologics License Application (BLA) submissions for **Revascor®** in end-stage heart failure and **Rexlemestrocel-L** for chronic low back pain.  **[1345099_0001345099-25-000068_exhibit991.htm:1]** **[1345099_0001345099-25-000068_exhibit991.htm:2]**

MESOBLAST (MESO)